Publications
242
Citations
14,575
Est. group size
—
Recurring co-author estimate
Active years
33
Publishing since 1993
Typically publishes in teams of ~13 · 11% small-team papers (≤3 authors) · across 25 venues
- Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG
Journal of bone oncology · 2025
- Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022
Annals of Oncology · 2024
- MASCC/ISOO Clinical Practice Statement: Adjuvant bone-modifying agents in primary breast cancer patients - prevention of medication-related osteonecrosis of the jaw
Supportive Care in Cancer · 2024
- Neratinib and Ado-Trastuzumab-Emtansine for Pre-treated and Untreated HER2-positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium Trial 022
UNC Libraries · 2024
- Quality of Life in Male Breast Cancer: Prospective Study of the International Male Breast Cancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG)
The Oncologist · 2023
- Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials
Breast Cancer Research and Treatment · 2023
- Checkpoint Inhibitors in Bone Metastatic Disease in Solid Tumors
Current Osteoporosis Reports · 2023
- Abstract PD7-03: Translational Breast Cancer Research Consortium Trial 022: Neratinib and Trastuzumab-Emtansine for HER2+ Breast Cancer Brain Metastases (BCBM)
Cancer Research · 2023
- Data from Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases
2023
- Data from Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases
2023
- Supplementary Data from Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases
2023
- Supplementary Data from Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases
2023
- 182P Radium-223 (223Ra) in combination with exemestane and everolimus (EXE-EVE) in patients (pts) with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC) with bone metastases: A phase II study
Annals of Oncology · 2022
- Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials
Research Square · 2022
- Effect of antiresorptive therapy on aromatase inhibitor induced bone loss in postmenopausal women with early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials
Metabolism · 2021
- Journal of Clinical Oncology×21
- Breast Cancer Research and Treatment×8
- Cancer Research×6
- Annals of Oncology×4
- Clinical Cancer Research×4
- Noriyoshi Kurihara
Medicine · Indiana University
- Jeffery J. Nielsen
Medicine · Purdue University West Lafayette
- Stewart A. Low
Medicine · Purdue University West Lafayette
- Matthew Smith
Medicine · University of Michigan
- Gregory A. Clines
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile